长春酰胺联合奥沙利铂对耐药卵巢癌患者的效果及患者SDF-1因子的影响  

Effect of Vinblastamide Combined with Oxaliplatin on Patients with Drug-resistant Ovarian Cancer and Sdf-1 Factor

作　　者：孙慧霞[1] 郭哲[1] 许静[1] SUN Huixia;GUO Zhe;XU Jing(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院

出　　处：《实用癌症杂志》2019年第12期2075-2077,共3页The Practical Journal of Cancer

摘　　要：目的探讨长春酰胺联合奥沙利铂对耐药卵巢癌患者的效果及患者SDF-1因子的影响。方法选取耐药卵巢癌患者82例,随机分为2组,对照组患者应用长春酰胺进行治疗,研究组患者在此基础上联合奥沙利铂进行治疗。结果研究组不良反应发生概率明显低于对照组(P<0.05)。研究组SDF-1 CXCR4趋化活性明显优于对照组(P<0.05)。研究组患者GOS评分高于对照组(P<0.05)。研究组治疗效果优于对照组(P<0.05)。结论应用长春酰胺联合奥沙利铂治疗耐药卵巢癌,临床疗效较为理想,同时还可以改善患者SDF-1因子,降低不良反应发生概率,提高患者GOS评分,具有良好的治疗效果,值得在临床上广泛应用。Objective To investigate the effect of vinblastamide combined with oxaliplatin on patients with drug-resistant ovarian cancer and the effect of SDF-1 factor.Methods A total of 82 patients with drug-resistant ovarian cancer were randomly divided into 2 groups.The control group was treated with vinblastine.The patients in the study group were combined with oxaliplatinum was treated.Results The incidence of adverse reactions in the study group was significantly lower than that of the control group(P<0.05).The chemotactic activity of SDF-1 CXCR4 in the study group was significantly better than that in the control group(P<0.05).The GOS score of the study group was higher than that of the control group(P<0.05);The treatment effect of the study group was better than that of the control group(P<0.05).Conclusion In the treatment of drug-resistant ovarian cancer patients,the application of vinblastine combined with oxaliplatin is effective,and it can improve the SDF-1 factor,reduce the incidence of adverse reactions,and improve the GOS score of patients.The therapeutic effect is worthy of being widely used in clinical practice.

关 键 词：长春酰胺 奥沙利铂 耐药卵巢癌 效果 SDF-1因子 

分 类 号：R737.31[医药卫生—肿瘤]